← Leaderboards
Gregory D Kirk
Johns Hopkins University
$60,349,977
Attributed
$80,281,943
Total exposure
28
Grants
25
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.6M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$89,587,031 · 30
By mechanism
U01$32,785,969 · 4
R01$30,178,634 · 6
U54$16,548,023 · 13
R56$3,203,031 · 1
R34$1,983,041 · 2
K12$1,778,353 · 1
Top collaborators
- Ponsiano Ocama10 shared
- Shruti H Mehta7 shared
- Todd T Brown5 shared
- Mark D Macek5 shared
- Brion S Maher5 shared
- Meredith C Mccormack5 shared
- John F Mcdyer5 shared
- Stefan David Baral4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Donald S. Burke$42,062,956
- Kathleen Schwarz$11,772,700
- George Dimopoulos Dimopoulos$18,341,513
- Diane E Griffin$24,000,430
- John D Groopman$13,586,469
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelCohortInvestigationHiv InfectionsResourcesCollaborationsPersonsResearch InfrastructureEpidemiologyRisk FactorsLinkAntiretroviral TherapyMultidisciplinaryClinical ResearchEtiologyMentorsHigh RiskFundingBaseAfricaAfrica South Of The SaharaPrimary Carcinoma Of The Liver CellsUgandaUniversities
Grant awards (130)
AIDS Linked to the IntraVenous Experience (ALIVE) Study$2,378,750
U01 · FY2025 · DA
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study$337,004
U01 · FY2025 · CA · contact PI
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study$223,400
U01 · FY2025 · CA · contact PI
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study$39,960
U01 · FY2025 · CA · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,436,595
U01 · FY2024 · DA
Study of HIV Infection in the Etiology of Lung Disease (SHIELD) AIR: Air Pollution Impact on Respiratory Health in HIV$1,061,380
R01 · FY2024 · HL
HIV and HCC in Africa: The H2A Consortium$987,283
U54 · FY2024 · CA · contact PI
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study$632,241
U01 · FY2024 · CA · contact PI
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma$301,027
U54 · FY2024 · CA · contact PI
H2A Admin Core$214,355
U54 · FY2024 · CA · contact PI
HIV and HCC in Africa: The H2A Consortium$124,783
U54 · FY2024 · CA · contact PI
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma$124,783
U54 · FY2024 · CA · contact PI
H2A Developmental Core$64,828
U54 · FY2024 · CA · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,437,098
U01 · FY2023 · DA
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$1,102,432
R01 · FY2023 · DA
Study of HIV Infection in the Etiology of Lung Disease (SHIELD) AIR: Air Pollution Impact on Respiratory Health in HIV$1,081,202
R01 · FY2023 · HL
HIV and HCC in Africa: The H2A Consortium$990,369
U54 · FY2023 · CA · contact PI
Baltimore Oral Epidemiology, Disease Effects, and HIV Evaluation Study (BEEHIVE)$910,391
R01 · FY2023 · DE
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma$270,293
U54 · FY2023 · CA · contact PI
H2A Admin Core$211,902
U54 · FY2023 · CA · contact PI
H2A Developmental Core$73,386
U54 · FY2023 · CA · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,480,863
U01 · FY2022 · DA
Study of HIV Infection in the Etiology of Lung Disease (SHIELD) AIR: Air Pollution Impact on Respiratory Health in HIV$1,086,270
R01 · FY2022 · HL
HIV and HCC in Africa: The H2A Consortium$990,617
U54 · FY2022 · CA · contact PI
Baltimore Oral Epidemiology, Disease Effects, and HIV Evaluation Study (BEEHIVE)$867,415
R01 · FY2022 · DE
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$850,704
R01 · FY2022 · DA
Johns Hopkins HIV and Heart, Lung, Blood & Sleep Disorders Training Program (H3TP)$419,296
K12 · FY2022 · HL · contact PI
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma$259,161
U54 · FY2022 · CA · contact PI
H2A Admin Core$221,395
U54 · FY2022 · CA · contact PI
Research Supplements to Promote Diversity in Health-Related Research$194,979
R01 · FY2022 · DE
H2A Developmental Core$57,098
U54 · FY2022 · CA · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,493,073
U01 · FY2021 · DA
Study of HIV Infection in the Etiology of Lung Disease (SHIELD) AIR: Air Pollution Impact on Respiratory Health in HIV$1,092,131
R01 · FY2021 · HL
HIV and HCC in Africa: The H2A Consortium$988,451
U54 · FY2021 · CA · contact PI
Baltimore Oral Epidemiology, Disease Effects, and HIV Evaluation Study (BEEHIVE)$882,834
R01 · FY2021 · DE
Johns Hopkins HIV and Heart, Lung, Blood & Sleep Disorders Training Program (H3TP)$419,813
K12 · FY2021 · HL · contact PI
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma$270,293
U54 · FY2021 · CA · contact PI
H2A Admin Core$212,247
U54 · FY2021 · CA · contact PI
H2A Developmental Core$73,386
U54 · FY2021 · CA · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,521,954
U01 · FY2020 · DA
Study of HIV Infection in the Etiology of Lung Disease (SHIELD) AIR: Air Pollution Impact on Respiratory Health in HIV$1,100,718
R01 · FY2020 · HL
HIV and HCC in Africa: The H2A Consortium$1,038,176
U54 · FY2020 · CA · contact PI
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$960,711
R01 · FY2020 · DA
Baltimore Oral Epidemiology, Disease Effects, and HIV Evaluation Study (BEEHIVE)$903,089
R01 · FY2020 · DE
Johns Hopkins HIV and Heart, Lung, Blood & Sleep Disorders Training Program (H3TP)$419,813
K12 · FY2020 · HL · contact PI
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma$332,518
U54 · FY2020 · CA · contact PI
H2A Admin Core$265,118
U54 · FY2020 · CA · contact PI
H2A Developmental Core$77,104
U54 · FY2020 · CA · contact PI
AIDS Linked to the IntraVenous Experience (ALIVE)$2,554,475
U01 · FY2019 · DA
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$1,468,790
R01 · FY2019 · DA
Johns Hopkins HIV and Heart, Lung, Blood & Sleep Disorders Training Program (H3TP)$419,836
K12 · FY2019 · HL · contact PI
The Role of HIV Infection in the Etiology and Clinical Manifestations of Hep Carcinoma$299,959
U54 · FY2019 · CA · contact PI
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium$299,959
U54 · FY2019 · CA · contact PI
Patient-Oriented Research and Mentorship in HIV and Non-Communicable Diseases$154,155
K24 · FY2019 · AI · contact PI
The AIDS Linked to the Intravenous Experience (ALIVE) Study$1,798,764
U01 · FY2018 · DA · contact PI
Pharmacogenomics of ART adherence and effectiveness in the ALIVE Cohort$1,389,208
R01 · FY2018 · DA
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium$914,483
U54 · FY2018 · CA · contact PI
Predictors consequences and mechanisms of accelerated lung aging in HIV$809,995
R01 · FY2018 · HL · contact PI
Pre Malignant Cirrhosis and Hepatocellular Carcinoma in HIV Infected Ugandans$271,398
U54 · FY2018 · CA · contact PI
The Role of HIV Infection in the Etiology and Clinical Manifestations of Hep Carcinoma$218,398
U54 · FY2018 · CA · contact PI
Biomarker and Analytical Core$162,881
U54 · FY2018 · CA · contact PI
Patient-Oriented Research and Mentorship in HIV and Non-Communicable Diseases$152,285
K24 · FY2018 · AI · contact PI
Adminstrative and Coordinating Core$150,844
U54 · FY2018 · CA · contact PI
Developmental Core$110,962
U54 · FY2018 · CA · contact PI
Johns Hopkins HIV and Heart, Lung, Blood & Sleep Disorders Training Program (H3TP)$99,595
K12 · FY2018 · HL · contact PI
The AIDS Linked to the Intravenous Experience (ALIVE) Study$1,791,772
U01 · FY2017 · DA · contact PI
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium$721,268
U54 · FY2017 · CA · contact PI
Immune Mechanisms of HIV-associated COPD$698,816
U01 · FY2017 · HL · contact PI
Pre Malignant Cirrhosis and Hepatocellular Carcinoma in HIV Infected Ugandans$222,764
U54 · FY2017 · CA · contact PI
The Role of HIV Infection in the Etiology and Clinical Manifestations of Hep Carcinoma$179,263
U54 · FY2017 · CA · contact PI
Patient-Oriented Research and Mentorship in HIV and Non-Communicable Diseases$152,953
K24 · FY2017 · AI · contact PI
Biomarker and Analytical Core$134,846
U54 · FY2017 · CA · contact PI
Adminstrative and Coordinating Core$121,948
U54 · FY2017 · CA · contact PI
Developmental Core$91,079
U54 · FY2017 · CA · contact PI
The AIDS Linked to the Intravenous Experience (ALIVE) Study$1,772,479
U01 · FY2016 · DA · contact PI
Predictors, consequences and mechanisms of accelerated lung aging in HIV$809,995
R01 · FY2016 · HL · contact PI
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium$749,900
U54 · FY2016 · CA · contact PI
Immune Mechanisms of HIV-associated COPD$698,816
U01 · FY2016 · HL · contact PI
Pre Malignant Cirrhosis and Hepatocellular Carcinoma in HIV Infected Ugandans$222,764
U54 · FY2016 · CA · contact PI
The Role of HIV Infection in the Etiology and Clinical Manifestations of Hep Carcinoma$179,263
U54 · FY2016 · CA · contact PI
Patient-Oriented Research and Mentorship in HIV and Non-Communicable Diseases$152,146
K24 · FY2016 · AI · contact PI
Biomarker and Analytical Core$134,846
U54 · FY2016 · CA · contact PI
Adminstrative and Coordinating Core$121,948
U54 · FY2016 · CA · contact PI
Developmental Core$91,079
U54 · FY2016 · CA · contact PI
The AIDS Linked to the Intravenous Experience (ALIVE) Study$1,772,707
U01 · FY2015 · DA · contact PI
Predictors, consequences and mechanisms of accelerated lung aging in HIV$797,845
R01 · FY2015 · HL · contact PI
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium$749,900
U54 · FY2015 · CA · contact PI
Immune Mechanisms of HIV-associated COPD$698,816
U01 · FY2015 · HL · contact PI
Pre Malignant Cirrhosis and Hepatocellular Carcinoma in HIV Infected Ugandans$222,764
U54 · FY2015 · CA · contact PI
The Role of HIV Infection in the Etiology and Clinical Manifestations of Hep Carcinoma$179,263
U54 · FY2015 · CA · contact PI
Patient-Oriented Research and Mentorship in HIV and Non-Communicable Diseases$154,146
K24 · FY2015 · AI · contact PI
Biomarker and Analytical Core$134,846
U54 · FY2015 · CA · contact PI
Adminstrative and Coordinating Core$121,948
U54 · FY2015 · CA · contact PI
Developmental Core$91,079
U54 · FY2015 · CA · contact PI
The AIDS Linked to the Intravenous Experience (ALIVE) Study$1,797,375
U01 · FY2014 · DA · contact PI
Predictors, consequences and mechanisms of accelerated lung aging in HIV$809,995
R01 · FY2014 · HL · contact PI
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium$749,899
U54 · FY2014 · CA · contact PI
Immune Mechanisms of HIV-associated COPD$684,841
U01 · FY2014 · HL · contact PI
Pre Malignant Cirrhosis and Hepatocellular Carcinoma in HIV Infected Ugandans$229,403
U54 · FY2014 · CA · contact PI
The Role of HIV Infection in the Etiology and Clinical Manifestations of Hep Carcinoma$184,851
U54 · FY2014 · CA · contact PI
Adminstrative and Coordinating Core$134,067
U54 · FY2014 · CA · contact PI
Biomarker and Analytical Core$108,301
U54 · FY2014 · CA · contact PI
Developmental Core$93,277
U54 · FY2014 · CA · contact PI
Natural History of HIV Infection In Injection Drug Users$1,572,631
R56 · FY2013 · DA · contact PI
Immune Mechanisms of HIV-associated COPD$678,027
U01 · FY2013 · HL · contact PI
Using mHealth to Respond Early to Acute Exacerbations of COPD in HIV_ mREACH$609,591
R34 · FY2013 · HL · contact PI
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care$356,514
R34 · FY2013 · DA · contact PI
Natural History of HIV Infection In Injection Drug Users$1,630,400
R56 · FY2012 · DA · contact PI
Using mHealth to Respond Early to Acute Exacerbations of COPD in HIV_ mREACH$645,722
R34 · FY2012 · HL · contact PI
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care$371,214
R34 · FY2012 · DA · contact PI
Natural History of HIV Infection in Injection Drug Users$1,417,584
R01 · FY2011 · DA · contact PI
The Study of HIV Infection in the Etiology of Lung Disease (SHIELD)$875,872
R01 · FY2011 · HL · contact PI
Natural History of HIV Infection in Injection Drug Users$1,636,763
R01 · FY2010 · DA · contact PI
The Study of HIV Infection in the Etiology of Lung Disease (SHIELD)$873,129
R01 · FY2010 · HL · contact PI
Epidemiology and Mechanisms of Accelerated Aging in HIV Infection$496,576
RC1 · FY2010 · AI · contact PI
Real Time Methods for Quantifying Exposure to Illicit Drugs & Psychosocial Stress$452,188
U01 · FY2010 · DA · contact PI
Natural History of HIV Infection in Injection Drug Users$37,490
R01 · FY2010 · DA · contact PI
Natural History of HIV Infection in Injection Drug Users$1,489,709
R01 · FY2009 · DA · contact PI
The Study of HIV Infection in the Etiology of Lung Disease (SHIELD)$889,680
R01 · FY2009 · HL · contact PI
Epidemiology and Mechanisms of Accelerated Aging in HIV Infection$498,606
RC1 · FY2009 · AI · contact PI
Real Time Methods for Quantifying Exposure to Illicit Drugs & Psychosocial Stress$456,755
U01 · FY2009 · DA · contact PI
Natural History of HIV Infection in Injection Drug Users$150,000
R01 · FY2009 · DA · contact PI
Natural History of HIV Infection in Injection Drug Users$1,406,374
R01 · FY2008 · DA · contact PI
The Study of HIV Infection in the Etiology of Lung Disease (SHIELD)$890,479
R01 · FY2008 · HL · contact PI
Real Time Methods for Quantifying Exposure to Illicit Drugs & Psychosocial Stress$456,753
U01 · FY2008 · DA · contact PI
Natural History of HIV Infection in Injection Drug Users$39,358
R01 · FY2008 · DA · contact PI
Natural History of HIV Infection in Injection Drug Users$1,436,215
R01 · FY2007 · DA · contact PI
The Study of HIV Infection in the Etiology of Lung Disease (SHIELD)$855,897
R01 · FY2007 · HL · contact PI
Real Time Methods for Quantifying Exposure to Illicit Drugs & Psychosocial Stress$492,447
U01 · FY2007 · DA · contact PI
Natural History of HIV Infection in Injection Drug Users$1,349,113
R37 · FY2006 · DA · contact PI